Tuesday, September 15, 2026
Ideas · Research · AI-powered analysis
Jun 2, 2026 ·NASDAQ TELEHEALTH
HIMSNASDAQLong

The Case for Hims & Hers Health: Why the Market is Wrong About the GLP-1 Shakeout

Updates

Jun 7, 2026
Verdict: The Direction Is Right. The Details Are Dangerously Incomplete.

What the article gets right ✅

The GLP-1 demand thesis is ironclad. The global GLP-1 receptor agonist market is expected to grow at a CAGR of 12.4% from 2026 to 2033, reaching approximately $185 billion by 2033. The article's core premise — that the market overreacted to the compounding ban — is defensible. The June 2, 2026 completion of the Eucalyptus deal expands Hims & Hers' global digital health footprint across Australia, Canada, Germany, Japan, and the UK, cementing its position as what it calls the world's largest consumer health platform. That's genuinely exciting. | Grand View Research | TipRanks |

Where the article failed its readers ❌

The balance sheet claim is factually wrong — and this is serious.The article says HIMS has "absolute zero long-term bank debt." That was already false when it was written. On May 21, 2026, Hims & Hers Health issued $402.5 million of senior unsecured convertible notes maturing June 1, 2032, with an initial conversion price of about $29.53 per share. This came on top of the $1.0B convertible notes already on the books from 2025. True convertible debt load: ~$1.4B. Net cash is now effectively negative when you back out the $751M in cash. The "fortress balance sheet" narrative was a significant omission. | TipRanks |

The Q1 miss was brutal, not "transitional." Hims & Hers missed Q1 2026 on revenue ($608.1M vs. consensus $616.85M) and earnings (–$0.40 EPS vs. expected $0.03), with restructuring costs pressuring profitability with a $92M GAAP net loss. That EPS miss is over 1,400%. The article doesn't mention it. | 24/7 Wall St. |

Margins are structurally compressed. Selling branded drugs at Novo's self-pay prices will likely generate lower margins than compounded alternatives. This transition, while strategically sound for removing regulatory risk, creates near-term headwinds for profitability. Gross margins fell from 73% → 65% in one quarter. Recovery is not guaranteed. | barchart |

Political risk is real and omitted. Senator Jim Banks reportedly urged the FDA to examine advertising, pricing and subscription practices at Hims & Hers and other telehealth providers, raising concerns about the marketing of compounded GLP-1 products and pricing of branded therapies like Zepbound. | Stocktwits |

Is the $38 target right?
Not in the near term. The consensus 12-month price target heading into Q1 results stood at $31.86, with short interest remaining elevated above 35% of the available float, equivalent to nearly 70 million shares held short. Post-Q1, BofA cut to $30, Leerink is at $25, and Truist is at $23. The article's $38 target is optimistic relative to where the Street actually sits. | Rolling Out |

My call as of June 7, 2026
Tactical HOLD, accumulate below $24. The long-term thesis is alive. It is estimated that upwards of 30 million Americans will be on GLP-1 treatment in 2030, an increase of 10 million from those on branded GLP-1s in 2026, making the growth of GLP-1s one of the key storylines to watch. HIMS is well-positioned for that wave. But the next critical data point is Q2 results on August 10, 2026 — if they hit the guided $680–700M, the stock rereates meaningfully. If they miss again, the bear case at $16–20 becomes credible fast. Don't chase this — let the Q2 report do the work. | J.P. Morgan |

Not investment advice. For educational purposes only.

Hims & Hers is an incredibly resilient, cash-rich digital health leader that the market has fundamentally mispriced at under 2.0x forward revenues due to a short-sighted overreaction to temporary GLP-1 compounding regulations.

Turning Regulatory Turbulence into an Asymmetric Buying Opportunity: The Case for Hims & Hers Health

The world of growth investing rarely offers second chances. When a hyper-growth company experiences a sharp 60% drawdown from its market highs, the investing community often reacts with panic rather than analytical curiosity. This is exactly what is happening with Hims & Hers Health, Inc. (NYSE: HIMS) today, June 2, 2026.

Trading at $27.58—down significantly from its multi-year high of $70.43—HIMS has been heavily penalized by the market following a series of recent regulatory updates regarding compounded weight-loss medications. However, a deeper look into the company’s financials, balance sheet, and international expansion reveals an entirely different story: a healthy, well-capitalized business model that is successfully executing a major strategic pivot.

Decoding the FDA Shift: What Actually Changed?

To understand why HIMS represents a compelling investment opportunity today, we must first look at the recent regulatory shifts. Between February and May of 2026, the US Food and Drug Administration (FDA) took decisive action to restrict mass-marketed, unapproved compounded GLP-1 weight-loss formulations. This culminated in the removal of semaglutide and tirzepatide from the 503B bulk drug substance compounding list.

The market reacted as if HIMS’ entire weight-loss business had vanished overnight. While these regulatory shifts did create an initial $65 million revenue headwind in Q1 2026 and compressed gross margins down to 65%, they did not halt the company’s momentum. Instead, they accelerated a necessary transition toward an authorized, fully compliant branded distribution model. By moving away from mass-scale compounding and leaning into branded partnerships, HIMS has effectively insulated itself from future regulatory headwinds.

The Hidden Engines: “Hers” and International Hyper-Growth

The market’s intense focus on the GLP-1 compounding issue has caused it to overlook two massive growth drivers that are rapidly transforming the company’s fundamentals.

First, the female-focused wellness segment, “Hers,” has reached significant operational scale. Growing at greater than 100% year-over-year through 2025, the Hers business is firmly on track to cross the $1.0 billion annual revenue milestone during 2026. This segment provides a highly resilient, diversified stream of recurring revenue that has nothing to do with the weight-loss headwinds.

Second, the company’s international expansion is delivering explosive results. In the Q1 2026 earnings report released on May 11, international revenue surged by a factor of ten, jumping to $78.0 million from just $7.0 million in the same quarter last year. Management now projects that its international business will reach a $1.0 billion annual run-rate within the next three years, establishing a powerful growth engine outside of the mature US market.

A Fortress Balance Sheet Offering Rare Downside Protection

In a volatile market environment, financial health is paramount. HIMS maintains one of the strongest balance sheets in the digital healthcare space, boasting over $751 million in cash and short-term investments as of March 31, 2026, and absolute zero long-term bank debt.

This financial strength gives management incredible flexibility. Not only can they comfortably fund their ongoing global infrastructure and technology upgrades, but they can also aggressively support their own stock. With $225 million remaining on its authorized share buyback program, the company has a highly effective mechanism to stabilize its share price and reward patient shareholders during periods of market weakness.

Valuation: The Math Simply Doesn’t Add Up

Despite temporary margin pressures from its strategic pivot, management recently raised its full-year 2026 revenue guidance to a range of $2.8 billion to $3.0 billion, with Adjusted EBITDA projected at $275 million to $350 million.

At a current market cap of roughly $6.38 billion, the stock trades at an Enterprise Value to Forward Revenue multiple of just 1.94x. For a digital health platform growing its top-line at 20-28% year-over-year with 65% gross margins and clear line-of-sight toward $6.5 billion in 2030 revenue, this multiple represents a significant historical undervaluation.

[HIMS Multi-Year Valuation Compression]
2024-2025 EV/Sales Peak: 4.5x - 6.0x  ===============>  Current June 2026 EV/Sales: 1.94x

The Investor Verdict

HIMS is currently in an classic “underappreciated” market phase. The consensus view remains focused on near-term regulatory adjustments and temporary accounting net losses. In contrast, the forward-looking contrarian view recognizes a structurally sound, highly agile business that is successfully diversifying its offerings and scaling globally.

With a conservative 12-month base case target price of $38.00, HIMS offers an attractive +37.78% upside potential from its current price of $27.58. For long-term growth investors, the current accumulation channel provides a highly compelling, asymmetric entry point into a secular digital health leader.

MANDATORY DISCLAIMER

Disclaimer: This report is for informational and educational purposes only and should not be considered investment advice, financial advice, or a recommendation to buy or sell any security. The analysis is based on publicly available information as of the report date (2 June 2026) and may become outdated. Investors should conduct their own due diligence, review official company filings, and consult a licensed financial advisor before making investment decisions. Investing in securities involves risk, including the possible loss of capital. Past performance does not guarantee future results.

At writing · HIMS USD 27.25
For informational purposes only. Not financial advice.